Phase I inpatient study of the safety and immunogenicity of H9N2 [influenza A virus vaccine-H9N2] (6-2) AA ca reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a live attenuated virus vaccine candidate for prevention of Avian influenza H9N2 infection in the event of a pandemic (study B)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Influenza A virus vaccine-H9N2 (Primary)
- Indications Influenza A virus H9N2 subtype
- Focus Pharmacodynamics
- 21 Jan 2008 Biomarkers information updated
- 18 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 09 May 2007 New trial record.